By packaging lipid nanoparticles with elements that decrease the fibrous nature of solid tumors, researchers can deliver CRISPR therapies in a more efficient manner.
This month marks ten years since CRISPR-Cas9 was repurposed as a gene editing system, so we’re looking back at what has been accomplished in a decade of CRISPR editing.
The makers of the CRISPR-based testing platform, called miSHERLOCK, say it could enable people at home or physicians in resource-limited environments to detect SARS-CoV-2—and eventually, other pathogens.